Profile data is unavailable for this security.
About the company
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
- Revenue in JPY (TTM)68.70bn
- Net income in JPY4.91bn
- Incorporated2021
- Employees1.63k
- LocationASKA Pharmaceutical Holdings Co Ltd2-5-1, ShibauraMINATO-KU 108-8532JapanJPN
- Phone+81 354848845
- Fax+81 354848351
- Websitehttps://www.aska-pharma-hd.co.jp
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seikagaku Corp | 35.86bn | -755.00m | 40.91bn | 1.08k | -- | 0.5385 | 30.69 | 1.14 | -13.84 | -13.84 | 656.96 | 1,337.18 | 0.4328 | 2.03 | 3.92 | 33,360,930.00 | -0.9099 | 3.60 | -0.9881 | 3.96 | 40.92 | 52.56 | -2.10 | 7.94 | 4.26 | -- | 0.0049 | 55.17 | 8.73 | 6.57 | -44.46 | -- | 18.48 | 2.90 |
| Daito Pharmaceutical Co Ltd | 51.20bn | 2.23bn | 42.38bn | 1.07k | 18.92 | 0.7984 | 6.39 | 0.8277 | 74.42 | 74.42 | 1,703.91 | 1,763.62 | 0.6544 | 2.16 | 2.76 | 47,716,680.00 | 2.90 | 5.12 | 3.71 | 6.67 | 17.63 | 21.75 | 4.43 | 7.35 | 1.31 | -- | 0.1739 | 24.48 | 7.99 | 2.39 | -42.09 | -13.52 | 20.45 | 14.00 |
| Fuji Pharma Co Ltd | 54.57bn | 2.33bn | 58.82bn | 1.76k | 24.75 | 1.21 | 9.35 | 1.08 | 95.46 | 95.46 | 2,233.29 | 1,959.48 | 0.5765 | 1.49 | 2.83 | 31,007,950.00 | 2.46 | 4.51 | 3.93 | 6.76 | 40.82 | 40.57 | 4.27 | 8.51 | 0.876 | 17.58 | 0.3885 | 25.98 | 12.01 | 8.87 | -51.19 | 7.55 | 8.07 | 7.94 |
| Oncolys Biopharma Inc | 28.55m | -2.06bn | 69.57bn | 35.00 | -- | 17.38 | -- | 2,437.03 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| ASKA Pharmaceutical Holdings Co Ltd | 68.70bn | 4.91bn | 72.05bn | 1.63k | 14.49 | 1.03 | 9.30 | 1.05 | 172.92 | 172.92 | 2,421.07 | 2,420.68 | 0.6729 | 1.37 | 3.62 | 42,094,980.00 | 4.93 | 5.50 | 6.64 | 7.07 | 48.33 | 47.56 | 7.32 | 7.98 | 1.23 | 75.35 | 0.1551 | 16.60 | 2.06 | 4.07 | -32.39 | 51.04 | 9.49 | 31.48 |
| Nxera Pharma Co Ltd | 29.62bn | -12.53bn | 82.99bn | 374.00 | -- | 1.36 | -- | 2.80 | -138.60 | -138.60 | 328.05 | 674.04 | 0.2069 | 0.8144 | 4.11 | -- | -8.75 | -3.79 | -9.90 | -4.16 | 72.32 | 80.12 | -42.31 | -22.17 | 1.90 | -1.30 | 0.4847 | -- | 2.71 | 27.35 | -158.99 | -- | 42.87 | -- |
| JCR Pharmaceuticals Co Ltd | 37.55bn | -2.44bn | 87.93bn | 987.00 | -- | 1.79 | 189.09 | 2.34 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Cuorips Inc | 355.69m | -764.60m | 90.51bn | 56.00 | -- | 18.03 | -- | 254.45 | -93.30 | -93.30 | 43.60 | 607.39 | 0.0656 | 3.33 | 238.00 | 6,351,607.00 | -14.20 | -- | -14.62 | -- | 76.69 | -- | -216.57 | -- | 36.81 | -- | 0.00 | -- | 658.40 | -- | -1.92 | -- | -- | -- |
| Kyorin Pharmaceutical Co Ltd | 133.26bn | 10.77bn | 101.97bn | 2.00k | 9.08 | 0.7037 | 6.63 | 0.7652 | 187.40 | 187.40 | 2,319.59 | 2,417.37 | 0.6927 | 1.08 | 2.93 | 66,695,200.00 | 5.60 | 3.34 | 7.03 | 4.16 | 45.32 | 45.89 | 8.08 | 5.11 | 2.05 | -- | 0.1746 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
Data as of Feb 20 2026. Currency figures normalised to ASKA Pharmaceutical Holdings Co Ltd's reporting currency: Japanese Yen JPY
27.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dalton Investments, Inc.as of 02 May 2025 | 2.67m | 9.30% |
| Rising Sun Management Ltd.as of 30 Sep 2025 | 2.40m | 8.34% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 694.99k | 2.42% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 658.80k | 2.29% |
| Nomura Asset Management Co., Ltd.as of 05 Feb 2026 | 595.90k | 2.07% |
| Amova Asset Management Co., Ltd.as of 06 Feb 2026 | 368.60k | 1.28% |
| Daiwa Asset Management Co. Ltd.as of 30 Jan 2026 | 266.80k | 0.93% |
| Amundi Japan Ltd.as of 20 Feb 2025 | 129.81k | 0.45% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024 | 115.50k | 0.40% |
| Asset Management One Co., Ltd.as of 05 Feb 2026 | 47.30k | 0.16% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
